Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

Simple item page
dc.contributor.authorBorja Cabrera, Gulnara Patricia
dc.contributor.authorMendes, Amanda Cruz
dc.contributor.authorSouza, Edilma Paraguai de
dc.contributor.authorOkada, Lilian Y. Hashimoto
dc.contributor.authorTrivellato, Fernando Antonio de Assis
dc.contributor.authorKawasaki, Jarbas Kiyoshi Alves
dc.contributor.authorCosta, Andreia Cerqueira
dc.contributor.authorReis, Alexandre Barbosa
dc.contributor.authorGenaro, Odair
dc.contributor.authorBatista, Leopoldina Maria Melo
dc.contributor.authorPalatnik, Marcos
dc.contributor.authorSouza, Clarisa Beatriz Palatnik de
dc.date.accessioned2012-07-10T18:37:26Z
dc.date.available2012-07-10T18:37:26Z
dc.date.issued2004
dc.description.abstractThe potential effect of the fucose mannose ligand (FML)-vaccine on immunotherapy of canine visceral leishmaniasis was assayed on five mongrel dogs experimentally infected withLeishmania donovani and on 21 Leishmania chagasi naturally infected dogs when seropositive to FML but completely asymptomatic. The clinical signs of the experimentally infected, symptomatic dogs only disappeared after the complete vaccination. Protection was obtained in 3/5 animals that remained asymptomatic, IDR positive and parasite free, 1 year after infection. Furthermore, the asymptomatic, FML-vaccine treated dogs showed stable anti-FML IgG1 levels, increasing IgG2 levels and 79–95% of positive DTH response, during the whole experiment. Twenty-two months after complete vaccination, no obits due to visceral leishmaniasis were recorded and 90% of these dogs were still asymptomatic, healthy and parasite free. On the other hand, 37% (17/46 dogs) kala-azar obits were recorded in a control group that received no treatment during the same period, and that was FML-seropositive and asymtpomatic at the beginning of the assay. Our results indicate that the FML-vaccine was effective in the immunotherapy against visceral leishmaniasis of asymptomatic infected dogs. Normal proportions of CD4 and CD21 lymphocytes were detected in PBMC by FACS analysis, in dogs submitted to immunotherapy, suggesting their non-infectious condition. All animals showed as well significantly increased percents of CD8 lymphocytes as expected for Quillajasaponin (QuilA) vaccine treatments.pt_BR
dc.identifier.citationBORJA CABRERA, G. P. et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine, v. 22, n. 17-17, p. 2234-2243, jun. 2004. Disponível em: <https://www.sciencedirect.com/science/article/pii/S0264410X03008399>. Acesso em: 10 jul. 2012.pt_BR
dc.identifier.issn0264410X
dc.identifier.urihttp://www.repositorio.ufop.br/handle/123456789/1067
dc.language.isoen_USpt_BR
dc.rights.licenseO periódico Vaccine concede permissão para depósito deste artigo no Repositório Institucional da UFOP. Número da licença: 3291410377562.
dc.subjectCanine visceral leishmaniasispt_BR
dc.subjectVaccinept_BR
dc.subjectKala-azarpt_BR
dc.subjectImmunotherapypt_BR
dc.subjectImmunochemotherapypt_BR
dc.titleEffective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
DEACL - Artigos publicados em periódicos